Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
326 studies found for:    Alemtuzumab
Show Display Options
Rank Status Study
1 Completed CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Alemtuzumab
2 Withdrawn Alemtuzumab and Rituximab in Aplastic Anemia
Condition: Aplastic Anemia
Intervention: Drug: Alemtuzumab and Rituximab
3 Completed
Has Results
Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
Conditions: Evidence of Liver Transplantation;   Rejection;   ALEMTUZUMAB/NATALIZUMAB [VA Drug Interaction]
Intervention: Drug: Alemtuzumab
4 Unknown  Alemtuzumab for ANCA Associated Refractory Vasculitis
Conditions: Vasculitis;   Microscopic Polyangiitis;   Granulomatosis With Polyangiitis;   Wegener's
Intervention: Drug: Alemtuzumab
5 Active, not recruiting A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
Condition: Leukemia
Interventions: Biological: Alemtuzumab;   Biological: Rituximab
6 Active, not recruiting Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects
Condition: Multiple Sclerosis
Interventions: Drug: Alemtuzumab;   Drug: Alemtuzumab immunotherapy
7 Active, not recruiting Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Alemtuzumab
8 Terminated Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
Condition: Leukemia
Intervention: Drug: Alemtuzumab
9 Active, not recruiting Advanced MRI Measures of Repair in Alemtuzumab Treated Patients
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: MabCampath-1h
10 Completed Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
Condition: Acute Lymphocytic Leukemia
Intervention: Drug: Alemtuzumab (CAMPATH 1H) associated to G-CSF
11 Terminated The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Alemtuzumab
12 Recruiting Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Palifermin;   Drug: Alemtuzumab
13 Completed Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab;   Drug: Alemtuzumab
14 Unknown  Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Intervention: Drug: Alemtuzumab
15 Terminated The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
Condition: Autoimmune Cytopenias
Intervention: Drug: Alemtuzumab
16 Completed Infections Associated With the Use of Alemtuzumab
Condition: Patients Treated With Alemtuzumab
Intervention:
17 Completed A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: alemtuzumab
18 Unknown  Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: Alemtuzumab and Rituximab combination
19 Recruiting Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
Condition: B-cell Chronic Lymphocytic Leukemia
Intervention: Biological: Alemtuzumab
20 Completed
Has Results
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Intervention: Biological: Alemtuzumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.